Patents by Inventor J. Scott Sawyer

J. Scott Sawyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment
    Patent number: 11845745
    Abstract: Pharmaceutical compounds, their methods of manufacture, and methods of treatment of mammals with pharmaceutical compounds are provided.
    Type: Grant
    Filed: September 16, 2021
    Date of Patent: December 19, 2023
    Assignee: Clavius Pharmaceuticals, LLC.
    Inventor: J. Scott Sawyer
  • TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT
    Publication number: 20220073514
    Abstract: Pharmaceutical compounds, their methods of manufacture, and methods of treatment of mammals with pharmaceutical compounds are provided.
    Type: Application
    Filed: September 16, 2021
    Publication date: March 10, 2022
    Inventor: J. Scott Sawyer
  • SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT
    Publication number: 20220064187
    Abstract: This disclosure relates to low molecular weight substituted imidazoles that inhibit the TGF-b signaling pathway. More specifically, this disclosure relates to methods of using said imidazoles for the treatment of diseases related to the TGF-b signaling pathways including, but not limited to, atherosclerosis, Marfan syndrome, Loeys-Dietz syndrome, obesity, diabetes, multiple sclerosis, keratoconus, idiopathic pulmonary fibrosis, Alzheimer's Disease, chronic kidney disease, and scleroderma.
    Type: Application
    Filed: August 22, 2019
    Publication date: March 3, 2022
    Inventor: J. Scott SAWYER
  • Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment
    Patent number: 11124509
    Abstract: Pharmaceutical compounds, their methods of manufacture, and methods of treatment of mammals with pharmaceutical compounds are provided.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: September 21, 2021
    Assignee: Clavius Pharmaceuticals, LLC.
    Inventor: J. Scott Sawyer
  • TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT
    Publication number: 20200239462
    Abstract: Pharmaceutical compounds, their methods of manufacture, and methods of treatment of mammals with pharmaceutical compounds are provided.
    Type: Application
    Filed: March 23, 2018
    Publication date: July 30, 2020
    Inventor: J. Scott Sawyer
  • Method of treating leukotriene caused diseases with N-benzyl dihydroindole LTD.sub.4 antagonists
    Patent number: 5622969
    Abstract: This invention relates to pharmaceutical N-benzyl dihydroindole compounds having the general formula: ##STR1## and their use as LTD.sub.4 antagonists.
    Type: Grant
    Filed: March 31, 1995
    Date of Patent: April 22, 1997
    Assignee: Eli Lilly and Company
    Inventor: J. Scott Sawyer
  • N-benzyl dihydroindole LTD.sub.4 antagonists
    Patent number: 5569764
    Abstract: This invention relates to pharmaceutical N-benzyl dihydroindole compounds having the general formula: ##STR1## and their use as LTD.sub.4 antagonists.
    Type: Grant
    Filed: March 31, 1995
    Date of Patent: October 29, 1996
    Assignee: Eli Lilly and Company
    Inventor: J. Scott Sawyer
  • Leukotriene B4 antagonists
    Patent number: 5552441
    Abstract: This invention provides certain 1,2,4,5 substituted benzene derivatives containing "acid" substituents derived from cyclic or heterocyclic moieties. These unique compounds are leukotriene B.sub.4 antagonists and formulations of these derivatives, and a method of using these derivatives for the treatment of conditions characterized by an excessive release of leukotrienes.
    Type: Grant
    Filed: February 14, 1994
    Date of Patent: September 3, 1996
    Assignee: Eli Lilly and Company
    Inventors: Robert D. Dillard, J. Scott Sawyer, Michael J. Sofia
  • N-benzyl dihydroindole LTD.sub.4 antagonists
    Patent number: 5486612
    Abstract: This invention relates to pharmaceutical N-benzyl dihydroindole compounds having the general formula: ##STR1## and their use as LTD.sub.4 antagonists.
    Type: Grant
    Filed: December 14, 1993
    Date of Patent: January 23, 1996
    Assignee: Eli Lilly and Company
    Inventor: J. Scott Sawyer
  • Substituted phenyl phenol leukotriene antagonists
    Patent number: 5462954
    Abstract: Antagonists having a substituted phenyl phenol or a substituted phenolic biphenyl structure, and various derivatives thereof, are specific leukotriene antagonists. Their structures, use and synthesis are disclosed. Also, pharmaceutical formulations are disclosed for use in applications treating diseases or conditions characterized by excessive release of leukotriene B.sub.4, one of the metabolites of arachidonic acid.The primary LTB.sub.
    Type: Grant
    Filed: November 1, 1994
    Date of Patent: October 31, 1995
    Assignee: Eli Lilly and Company
    Inventors: S. Richard Baker, Robert D. Dillard, Paul E. Floreancig, J. Scott Sawyer, Michael J. Sofia
  • Leukotriene B.sub.4 antagonists
    Patent number: 5324743
    Abstract: This invention provides certain 1,2,4,5 substituted benzene derivatives containing "acid" substituents derived from cyclic or heterocyclic moieties. These unique compounds are leukotriene B.sub.4 antagonists and formulations of these derivatives, and a method of using these derivatives for the treatment of conditions characterized by an excessive release of leukotrienes.
    Type: Grant
    Filed: December 10, 1992
    Date of Patent: June 28, 1994
    Assignee: Eli Lilly and Company
    Inventors: Robert D. Dillard, J. Scott Sawyer, Michael J. Sofia